World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
67
Citations
23811
World Ranking
2642
National Ranking
1261

Alexander Fefer publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Alexander Fefer sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 171 publications — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Alexander Fefer D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Alexander Fefer sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 67 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Alexander Fefer was affiliated with the University of Washington in the United States. Their research primarily focused on the intersection of mathematics and decision sciences, with significant contributions in statistics and probability, management science and operations research, computational theory and mathematics, as well as economics and econometrics.

Their scholarly output included extensive work on statistical methods, particularly in clinical trials and optimal experimental design. Key research topics covered by Fefer included:

  • Statistical Methods in Clinical Trials
  • Optimal Experimental Design Methods
  • Advanced Statistical Process Monitoring
  • Advanced Causal Inference Techniques
  • Statistical Methods and Inference
  • Health Systems, Economic Evaluations, Quality of Life
  • Biosimilars and Bioanalytical Methods

Fefer's publication record featured collaborations with various frequent coauthors such as Sergey Tarima, James L. Rosenberger, Kelly Van Lancker, Madeline Bauer, and Jonathan W. Bartlett. Their work was often published in venues including:

  • Statistics in Biopharmaceutical Research
  • Statistical Papers
  • arXiv (Cornell University)
  • Biometrics
  • Anesthesiology

Notable recent papers by Fefer included:

  • Understanding Research Methods: Up-and-down Designs for Dose-finding, 2022, Anesthesiology
  • Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions, 2022, Statistics in Biopharmaceutical Research
  • Design Considerations for Two-Stage Enrichment Clinical Trials, 2022, Biometrics
  • Coping with Information Loss and the Use of Auxiliary Sources of Data: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions, 2023, Statistics in Biopharmaceutical Research
  • Inference for a two-stage enrichment design, 2021, The Annals of Statistics

Throughout their career, Fefer's research emphasized methods that address challenges in clinical trial design and analysis, including trials affected by external disruptions such as the COVID-19 pandemic. Their interdisciplinary approach integrated advanced statistical inference techniques with practical decision sciences applications, delivering insights relevant to health systems and bioanalytics.

Best Publications

  • Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

    Glucksberg H;Storb R;Fefer A;Buckner Cd

  • Bone-marrow transplantation (first of two parts).

    E Thomas;R Storb;R A Clift;A Fefer

  • Bone-marrow transplantation (second of two parts).

    Thomas Ed;Storb R;Clift Ra;Fefer A

  • One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

    ED Thomas;CD Buckner;M Banaji;RA Clift

  • Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia

    K M Sullivan;P L Weiden;R Storb;R P Witherspoon

  • Effects of In Vitro Depletion of T Cells in HLA-Identical Allogeneic Marrow Grafts

    PJ Martin;JA Hansen;CD Buckner;JE Sanders

  • Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia [published erratum appears in Blood 1989 Aug 15;74(3):1180]

    KM Sullivan;PL Weiden;R Storb;RP Witherspoon

  • Marrow Transplantation for the Treatment of Chronic Myelogenous Leukemia

    E D Thomas;R A Clift;A Fefer;F R Appelbaum

  • Hickman Catheter Infections in Patients With Malignancies

    Oliver W. Press;Paul G. Ramsey;Eric B. Larson;Alexander Fefer

  • Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

    P D Greenberg;M A Cheever;A Fefer

  • Graft-versus-Host Disease as Adoptive Immunotherapy in Patients with Advanced Hematologic Neoplasms

    K M Sullivan;R Storb;C D Buckner;A Fefer

  • Allogeneic marrow grafting for treatment of aplastic anemia.

    R. Storb;E. D. Thomas;C. D. Buckner;R. A. Clift

  • Marrow transplantation for acute nonlymphoblastic leukemia in first remission using fractionated or single-dose irradiation

    E.D. Thomas;R.A. Clift;J. Hersman;J.E. Sanders

  • Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

    M A Cheever;P D Greenberg;A Fefer;S Gillis

  • Aplastic anaemia treated by marrow transplantation.

    E Donnall Thomas;Rainer Storb;Alexander Fefer;SherillJ Slichter

  • Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation.

    F R Appelbaum;K M Sullivan;C D Buckner;R A Clift

  • Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle.

    R. Storb;E. D. Thomas;P. L. Weiden;C. D. Buckner;C. D. Buckner;C. D. Buckner

  • High-dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow

    C. D. Buckner;R. H. Rudolph;A. Fefer;R. A. Clift

  • Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.

    H. J. Deeg;H. M. Shulman;J. E. Anderson;E. M. Bryant

  • Bone Marrow Transplantation or Chemotherapy After Remission Induction for Adults with Acute Nonlymphoblastic Leukemia: A Prospective Comparison

    Appelbaum Fr;Dahlberg S;Thomas Ed;Buckner Cd

  • Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects

    John A. Thompson;Douglas J. Lee;Pamela Kidd;Ellen Rubin

  • Treatment of Established Human Graft-Versus-Host Disease by Antithymocyte Globulin

    R Storb;E Gluckman;E D Thomas;C D Buckner

  • Bone Marrow Transplantation in Patients Aged 45 Years and Older

    HG Klingemann;R Storb;A Fefer;HJ Deeg

  • Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease.

    K Atkinson;V Farewell;R Storb;Tsoi

Frequent Co-Authors

Martin A. Cheever
Martin A. Cheever University of Washington
E. Donnall Thomas
E. Donnall Thomas University of Washington
Paul E. Neiman
Paul E. Neiman Fred Hutchinson Cancer Research Center
Jean E. Sanders
Jean E. Sanders Fred Hutchinson Cancer Research Center
Philip D. Greenberg
Philip D. Greenberg Fred Hutchinson Cancer Research Center
Rainer Storb
Rainer Storb Fred Hutchinson Cancer Research Center
Keith M. Sullivan
Keith M. Sullivan Duke University
Buckner Cd
Buckner Cd National Cancer Institute
Robert P. Witherspoon
Robert P. Witherspoon Fred Hutchinson Cancer Research Center
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can broaden career opportunities. Transitioning within nursing specialties is a common pathway. For example, a fnp to acute care np bridge program helps Family Nurse Practitioners move into acute care settings, allowing for specialized patient care that often intersects with immunological disorders.

Accelerated nursing programs are crucial for students aiming to fast-track their careers. Many students benefit from accelerated np programs online, which offer flexible learning models without compromising quality. These programs can support one’s growth in understanding immune system-related health issues at a practitioner level.

For those without a nursing background, starting an accelerated nursing education is achievable. Both online absn programs for non nurses and accelerated bsn programs for non nurses provide practical and accessible entry points. These paths are designed to quickly prepare students for nursing roles, ultimately supporting diverse career options within immunology and related fields.

Best Scientists Citing Alexander Fefer

Recently Published Articles